Weekly shot may help 'double diabetes' patients control blood sugar
NCT ID NCT05305794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a weekly injection of semaglutide (a GLP-1 drug) in 76 adults with 'double diabetes' — a mix of type 1 diabetes and inherited insulin resistance. The goal is to see if the drug improves blood sugar control and helps with weight loss. Participants must be over 18, have type 1 diabetes, a BMI of 27 or higher, and a family history of type 2 diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 76 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2022
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Person who has given written consent * Patient over 18 years of age * Patient with type 1 diabetes confirmed by a C-peptide below laboratory standards * Age at diagnosis \< 35 years * Treated with optimized insulin therapy (multi-injections or pump) for at least 1 year, having received specific therapeutic education on insulin dose adaptation. * BMI (weight/height2) ≥ 27 Kg/m². * At least one of the following criteria: * Family history of type 2 diabetes (parents, grandparents, uncles, aunts, brothers and sisters) * Family history of obesity (BMI\>30 Kg/m2) (parents, grandparents, uncles, aunts, siblings) * Triglycerides \> 1.50g/l (1.7mmol/l) * HDL\< 0.5 g/l (1.29 mmol/l) in women, HDL\<0.4 g/l (1.03 mmol/l) in men * HbA1c ≥ 7.5% and \< 12% in the 3 months preceding inclusion * Having continuous glucose monitoring by a CGM (Holter Glucose Monitoring) system: Guardian, Dexcom or Free Style Libre * For women of childbearing age: using an effective method of contraception until 2 months after the end of treatment. Effective contraception includes: hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomy and sexual abstinence Exclusion Criteria: * person not affiliated to national health insurance * Pregnant, parturient or breastfeeding woman * HbA1c ≥12% in the 3 months preceding inclusion. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, confirmed by a fundus examination performed in the 6 months preceding the selection * Person under a measure of legal protection (curatorship, guardianship) * Renal insufficiency (GFR\<30 ml/mn) * Hepatic insufficiency (INR\> 1.5) * BMI \>40 kg/m². * History of bariatric surgery * History of pancreatitis * Allergy to the active substance or to one of the excipients of OZEMPIC®. * Patients treated with GLP1 agonists or oral antidiabetics in the month preceding month prior to inclusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Double diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chu Dijon Bourgogne
RECRUITINGDijon, 21000, France